Finance

Lists
BIIB34:BVMF
Biogen Inc BDR
230,10 R$
0,00%
(0,00) 1D
4 նոյ, 15:38:07 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB34...
Mkt. cap
37,03 մլրդ
Avg. vol.
9,00
Volume
0,00
52-wk high
230,10 R$
52-wk low
137,90 R$
Shares outstanding
147,82 մլն
No. of employees
8 հզր
Mkt. cap
37,03 մլրդ
Avg. vol.
9,00
Volume
0,00
52-wk high
230,10 R$
52-wk low
137,90 R$
Shares outstanding
147,82 մլն
No. of employees
8 հզր
News stories
From web sources and news partners
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7,5 հզր
Founded1978
HeadquartersՔեմբրիջ, Մասսաչուսեթս, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websitebiogen.com
Last report
28 հոկ, 2026 թ.
Fiscal period
Q3 2026
2,62 $ / 1,99 $
+31,53%beat
Revenue / Est. (USD)
2,80 մլրդ / 2,63 մլրդ
+6,56%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
2,28 մլրդ
2,48 մլրդ
2,74 մլրդ
2,80 մլրդ
Cost of goods sold
443,40 մլն
1,09 մլրդ
1,10 մլրդ
1,13 մլրդ
Cost of revenue
443,40 մլն
1,09 մլրդ
1,10 մլրդ
1,13 մլրդ
Research and development expenses
477,10 մլն
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
685,20 մլն
607,30 մլն
709,70 մլն
752,00 մլն
Operating expense
1,36 մլրդ
818,00 մլն
946,70 մլն
1,00 մլրդ
Total operating expenses
1,81 մլրդ
1,91 մլրդ
2,05 մլրդ
2,13 մլրդ
Operating income
471,60 մլն
567,40 մլն
685,60 մլն
676,30 մլն
Other non operating income
17,40 մլն
-1,10 մլն
3,00 մլն
11,20 մլն
EBT including unusual items
-56,00 մլն
377,70 մլն
132,40 մլն
-9,00 մլն
EBT excluding unusual items
447,00 մլն
530,10 մլն
625,10 մլն
603,00 մլն
Income tax expense
-7,10 մլն
58,20 մլն
34,90 մլն
11,60 մլն
Effective tax rate
12,68%
15,41%
26,36%
-128,89%
Other operating expenses
69,90 մլն
74,20 մլն
68,80 մլն
77,80 մլն
Net income
-48,90 մլն
319,50 մլն
97,50 մլն
-20,60 մլն
Net profit margin
-2,15%
12,89%
3,56%
-0,73%
Earnings per share
1,99
3,57
3,60
2,62
Interest and investment income
37,20 մլն
37,90 մլն
25,30 մլն
9,30 մլն
Interest expense
-67,50 մլն
-67,60 մլն
-82,30 մլն
-87,50 մլն
Net interest expenses
-30,30 մլն
-29,70 մլն
-57,00 մլն
-78,20 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
671,80 մլն
771,80 մլն
921,70 մլն
917,40 մլն
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google Apps